开始
Investor4321

AVEO Could Rise 200+% On The 15th

Investor4321  
NASDAQ:AVEO   None
Fundamental Analysis
5
2
fundamental
This company is releasing data for phase one clinical trial data for a cancer treatment drug. The risk is high, but if the data is good, The stock could rise 200+%.

相关观点

Investor4321
$PENN Swing Idea, Target $130
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。